StockNews.com Begins Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)

StockNews.com started coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research report report published on Wednesday morning. The brokerage issued a sell rating on the stock.

Separately, Alliance Global Partners upped their target price on shares of Tonix Pharmaceuticals from $6.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, July 22nd.

Tonix Pharmaceuticals Stock Performance

TNXP stock opened at $0.13 on Wednesday. The company has a quick ratio of 0.72, a current ratio of 1.15 and a debt-to-equity ratio of 0.13. Tonix Pharmaceuticals has a twelve month low of $0.12 and a twelve month high of $22.14. The business’s fifty day moving average is $0.15 and its 200-day moving average is $1.44. The company has a market cap of $17.99 million, a P/E ratio of 0.00 and a beta of 2.06.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. The firm had revenue of $2.82 million for the quarter, compared to analysts’ expectations of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 158.64% and a negative net margin of 1,197.86%. Equities research analysts forecast that Tonix Pharmaceuticals will post -18 EPS for the current year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Acadian Asset Management LLC lifted its holdings in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 335,373 shares of the company’s stock after purchasing an additional 242,358 shares during the quarter. Acadian Asset Management LLC owned about 0.40% of Tonix Pharmaceuticals worth $61,000 as of its most recent SEC filing. Institutional investors and hedge funds own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.